Efficacy and Safety of Pasireotide Administered Monthly in Patients With Cushing's Disease
NCT01374906
·
clinicaltrials.gov ↗
PHASE3
Phase
COMPLETED
Status
150
Enrollment
INDUSTRY
Sponsor class
Conditions
Cushing's Disease
Interventions
DRUG:
pasireotide LAR
DRUG:
SOM230 LAR 30 mg
DRUG:
SOM230 LAR 10 mg
Sponsor
Novartis Pharmaceuticals